ArticleNature2024
A µ-opioid receptor modulator that works cooperatively with naloxone.
Abstract read
In one paragraph
Article in Nature, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Comparative Study of Analgesic Therapeutic Index and Addiction Potential of o- and p-Fluorofentanyl.Journal of applied toxicology : JAT · 2026Article
- Landscaping the Nitazene Scaffold to Identify Novel Mu-Opioid Receptor Modulators: From Molecular Design and Chemical Synthesis to Pharmacological Profiling.Journal of medicinal chemistry · 2026Article
- Hold on tight: the kinetic profiling of opioid receptor ligands using the CORAL-MD.Journal of cheminformatics · 2026Article
- Molecular mechanism of allosteric modulation of opioid receptors.Signal transduction and targeted therapy · 2026Article
- Discovery of membrane channel modulators via DNA encoded library screening using native like membrane protein nanoparticles.Scientific reports · 2026Article
- Does Kappa Agonism Improve Reversal of 'Tranq-Dope' Overdose? Evidence from a Rodent Model.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Recent Advances in GPCR Ligand Discovery Using DNA-Encoded Library Technology: From Affinity Binding to Functional Bias and Allosteric Modulation.ACS medicinal chemistry letters · 2026Review
- Structural and dynamic studies uncover a distinct allosteric modulatory site at the µ-opioid receptor.Nature communications · 2026Article
- Mechanism-guided identification of antidepressant G protein-coupled receptor drug targets.Cell · 2026Article
- Discovery and dynamic pharmacology of μ-opioid receptor positive allosteric modulators.bioRxiv : the preprint server for biology · 2026Article
- Acute fentanyl and xylazine co-exposure uniquely increase the excitability of dopamine type 2 receptor-expressing striatal medium spiny neurons.Journal of neurophysiology · 2026Article
- Strategic advances for cryo-EM structural studies of small (<100 kDa) GPCRs.Communications biology · 2026Review
- Structural Perspectives on Biased Allostery of GPCR Signaling.Handbook of experimental pharmacology · 2026Review
- The Human Omnibus of Targetable Pockets.Journal of cheminformatics · 2025Article
- The neural circuits and signalling pathways of opioid use disorder.Nature reviews. Neuroscience · 2025Review
- Extracellular nanobody screening using conformationally stable GPCR variants.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Reversing the triad of anaesthesia in a cannot intubate, cannot oxygenate emergency. Comment on Br J Anaesth 2024; 133: 190-2.British journal of anaesthesia · 2025Article
- Is Fentanyl Rebound an Intrinsic Feature of Naloxone Reversal?Pharmaceuticals (Basel, Switzerland) · 2025Article
- Structural and dynamic studies uncover a distinct allosteric modulatory site at the μ-opioid receptor.bioRxiv : the preprint server for biology · 2025Article
- De novo design of a fusion protein tool for GPCR research.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
Corrections and comments
- Commented on by
Authors and funding
19 authors.
Evan S O'BrienDepartment of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0002-2260-7722
Vipin Ashok RangariCenter for Clinical Pharmacology, University of Health Sciences and Pharmacy at St Louis and Washington University School of Medicine, St Louis, MO, USA.ORCID 0000-0002-9721-6195
Amal El DaibaniCenter for Clinical Pharmacology, University of Health Sciences and Pharmacy at St Louis and Washington University School of Medicine, St Louis, MO, USA.
Shainnel O EansDepartment of Pharmacodynamics, University of Florida, Gainesville, FL, USA.
Haylee R HammondDepartment of Pharmacodynamics, University of Florida, Gainesville, FL, USA.
Elizabeth WhiteDepartment of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA.
Haoqing WangDepartment of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA.
Yuki ShiimuraDepartment of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA.
Kaavya Krishna KumarDepartment of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0003-2283-4033
Qianru JiangCenter for Clinical Pharmacology, University of Health Sciences and Pharmacy at St Louis and Washington University School of Medicine, St Louis, MO, USA.
Kevin AppourchauxCenter for Clinical Pharmacology, University of Health Sciences and Pharmacy at St Louis and Washington University School of Medicine, St Louis, MO, USA.ORCID 0000-0001-9853-3347
Weijiao HuangDepartment of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA.
Chensong ZhangDivision of CryoEM and Bioimaging, SSRL, SLAC National Acceleration Laboratory, Menlo Park, CA, USA.
Brandon J KennedyLotus Separations, Princeton University, Princeton, NJ, USA.ORCID 0000-0003-1892-8926
Jesper M MathiesenDepartment of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark.
Tao CheCenter for Clinical Pharmacology, University of Health Sciences and Pharmacy at St Louis and Washington University School of Medicine, St Louis, MO, USA.ORCID 0000-0002-1620-3027
Jay P McLaughlinDepartment of Pharmacodynamics, University of Florida, Gainesville, FL, USA. jpmclaughlin@ufl.edu.ORCID 0000-0001-9851-9342
Susruta MajumdarCenter for Clinical Pharmacology, University of Health Sciences and Pharmacy at St Louis and Washington University School of Medicine, St Louis, MO, USA. susrutam@wustl.edu.ORCID 0000-0002-2931-3823
Brian K KobilkaDepartment of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA. kobilka@stanford.edu.ORCID 0000-0001-5958-3990
Funding
Targeting the allosteric sodium site with novel probes for delta opioid receptorR01DA057790 · NIDA · WASHINGTON UNIVERSITY · PI Tao Che, VSEVOLOD KATRITCH · 2023 to 2026
$2.6MThe structural basis for pathway-selective signaling by the µ opioid receptorR01DA036246 · NIDA · STANFORD UNIVERSITY · PI Brian K Kobilka · 2024 to 2026
$1.6MNIDA NIH HHS R01 DA036246NIDA NIH HHS R01 DA057790
Abstract
The µ-opioid receptor (µOR) is a well-established target for analgesia
Indexed as
Analgesics, OpioidDrug Evaluation, PreclinicalNaloxoneReceptors, Opioid, muSmall Molecule LibrariesAllosteric RegulationAnimalsBinding SitesCryoelectron MicroscopyFentanylHumansKineticsLigandsMaleMiceMice, Inbred C57BLAnalgesics, OpioidFentanylLigandsMorphineNaloxoneNarcotic AntagonistsReceptors, Opioid, muSmall Molecule Libraries
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.